Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SJ-Neo006
- Development stage
- Phase 1
- Lead developer
- Jiangsu Synthgene Biotechnology
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Not Explicitly Specified (likely Injection Or Infusion Typical For Vaccines)
01
Overview
SJ-Neo006 is a personalized neoantigen mRNA vaccine developed as an immunostimulant therapeutic vaccine aimed at treating cancers, specifically pancreatic ductal adenocarcinoma. It works by stimulating the immune system to recognize and attack tumor cells through neoantigens encoded in the mRNA. The drug is designed to be administered after surgical resection of tumors, often in combination with other therapies such as camrelizumab and chemotherapy agents like gemcitabine and abraxane. It is currently in early clinical development phases for pancreatic cancer treatment. The developer is Jiangsu Synthgene Biotechnology Co., Ltd., with clinical trials sponsored by Affiliated Jinling Hospital, Medical School of Nanjing University in China.[1][2][3][6]
- Other names
- Neoantigen mRNA Vaccines
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on SJ-Neo006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SJ-Neo006.